Ultragenyx Pharmaceutical Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Ultragenyx reported Q2 2026 total revenue of $214M (vs. $167M YoY), with Crysvita at $156M and Dojolvi at $27M. The company reaffirmed full-year 2026 revenue guidance of $730M–$760M and confirmed R&D/SG&A expenses flat to slightly down vs. 2025; guided to profitability in 2027 with ≥15% R&D/SG&A reduction. Cash position is $436M (down from $737M at end-2025); net loss Q2 was $92M ($0.90/share). Key catalysts: two PDUFA decisions (DTX401 by Aug 23, UX111 by Sept 19) and GTX-102 Phase 3 Aspire data expected Sept–Oct 2026.
Why this rating
Revenue growth and profitability timeline are meaningful positive signals; however, massive cash burn ($97M/quarter ops, $301M H1 2026) against $436M cash and widening stockholders' deficit (-$291M) create near-term runway concerns. Relative to $3.4B market cap, revenue is ~6% annual run-rate; catalysts are real but execution risk remains high for pre-revenue gene therapies.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.